js","6773","static/chunks/6773-061975b7a13f2526.js","3763","static/chunks/3763-5031c38f7a5044a1.js","4777","static/chunks/4777-7fa79cea095b0267.js","5071","static/chunks/5071-1aaad1643fd0f3d9.js","8631","static/chunks/8631-6612905842e66f05.js","3956","static/chunks/3956-445a540d184d91db.js","7952","static/chunks/7952-ee4e3ac10fbedfda.js","512","static/chunks/512-bcb290eabed856c4.js","7759","static/chunks/7759-79303bb83414620d.js","5422","static/chunks/5422-29b2c0073e365b16.js","2507","static/chunks/2507-ee0144f0fb20ac76.js","8492","static/chunks/8492-f17ab3216fe361f9.js","2785","static/chunks/2785-116580b35f1bb322.js","8368","static/chunks/8368-438d4be7dd683dfc.js","9080","static/chunks/9080-238ac880c12fda6b.js","7072","static/chunks/7072-530245caea10a4c5.js","3192","static/chunks/3192-edaab38c2fdeb6ab.js","3077","static/chunks/3077-c474095a61bd66c9.js","8234","static/chunks/8234-bf699f647ee74353.js","4589","static/chunks/4589-5b05633819f33918.js","229","static/chunks/229-db5ac014176aaf5b.js","5458","static/chunks/app/dashboard/episodes/%5Bid%5D/page-249b9fb0028b9980.js"],"EpisodeRecommend"] 23:T75c,

Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This Week podcast, Executive Editor Selina Koch discusses how tau could be reaching a tipping point. Also on this week’s episode, Washington Editor Steve Usdin details how political moves have begun to intrude into the Trump administration’s regulation of vaccines, a topic that’s also taken up by Phil Krause and Luciana Borio in a BioCentury Guest Commentary published Monday. BioCentury’s editors then discuss delays for drug regulation at FDA, Merck KGaA's $3.9 billion deal to acq

Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs

BioCentury This Week